aminocaproic acid has been researched along with Renal Insufficiency in 6 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
Excerpt | Relevance | Reference |
---|---|---|
" However, these studies have been criticized for including multiple centers and different dosing strategies." | 1.35 | Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients. ( Lee, PH; Murphy, SA; Olenchock, SA; Symes, J; Tolis, G; Yehoshua, T, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Makhija, N | 1 |
Sarupria, A | 1 |
Kumar Choudhary, S | 1 |
Das, S | 1 |
Lakshmy, R | 1 |
Kiran, U | 1 |
Weyand, AC | 1 |
Lombel, RM | 1 |
Pipe, SW | 1 |
Shavit, JA | 1 |
Olenchock, SA | 1 |
Lee, PH | 1 |
Yehoshua, T | 1 |
Murphy, SA | 1 |
Symes, J | 1 |
Tolis, G | 1 |
Hutton, B | 1 |
Joseph, L | 1 |
Fergusson, D | 1 |
Mazer, CD | 2 |
Shapiro, S | 1 |
Tinmouth, A | 1 |
LAGRUE, G | 1 |
MILLIEZ, P | 1 |
Body, SC | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
Intervention | grams per deciliter (Mean) |
---|---|
Tranexamic Acid | -1.8 |
Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
Intervention | days (Median) |
---|---|
Tranexamic Acid | 3 |
Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 35 |
Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 108 |
Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 233 |
Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 892 |
Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 20 |
Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 29 |
Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 649 |
Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 12 |
Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 339 |
Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 201 |
Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 162 |
Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 2 |
Placebo | 0 |
2 reviews available for aminocaproic acid and Renal Insufficiency
Article | Year |
---|---|
Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2012 |
[NEPHROLOGY IN 1964].
Topics: Acute Kidney Injury; Aminocaproates; Aminocaproic Acid; Antineoplastic Agents; Diabetes Mellitus; Di | 1964 |
1 trial available for aminocaproic acid and Renal Insufficiency
Article | Year |
---|---|
Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aorta, Thoracic; Blood Loss, Surgical; Blood Tran | 2013 |
3 other studies available for aminocaproic acid and Renal Insufficiency
Article | Year |
---|---|
The Role of Platelets and ε-Aminocaproic Acid in Arthrogryposis, Renal Dysfunction, and Cholestasis (ARC) Syndrome Associated Hemorrhage.
Topics: Aminocaproic Acid; Arthrogryposis; Blood Platelets; Cholestasis; Female; Hemorrhage; Heterozygote; H | 2016 |
Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Coronary Artery Bypass; Female; Humans; | 2008 |
Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery.
Topics: Aminocaproic Acid; Animals; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Drug Hyper | 2006 |